Abcam, ab237640, Rituximab ELISA Kit

Size: 96Test
Rituximab ELISA Kit is a sandwich ELISA designed to quantify free Rituximab with a sensitivity of 3 ng/mL. - Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader - Can be used for pharmacokinetic (PK) studies - Wide dynamic range - quantifies 3 - 100 ng/mL - For Research Use Only - Not intended for diagnostic use
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Serum,
Reacts with:Human,
Assay type:Quantitative,
Sensitivity:= 3 ng/mL,
Range:3 - 100 ng/mL,
Assay Platform:Microplate

Product details:
Note: Rituximab ELISA kit ab237640 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Rituximab in the sample or standard. Results of samples can be determined directly using the standard curve.
This assay measures only free Rituximab.
This product is manufactured by BioVision, an Abcam company and was previously called E4371 BioSim™ Rituximab (Human) ELISA Kit. E4371-100 is the same size as the 96 test size of ab237640.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Rituximab also known as anti-CD20 is a monoclonal antibody that targets the CD20 protein expressed on the surface of B cells. The CD20 protein is a non-glycosylated phosphoprotein with a mass of approximately 33 to 37 kilodaltons. It is expressed in both normal and malignant B cells from the pre-B-cell stage through the mature B-cell stage. The protein is absent in pro-B cells and plasma cells which helps in the specific targeting of B cells without affecting the stem cells or other immune cells.
Biological function summary
Rituximab depletes B cells by inducing cell lysis through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab’s binding to CD20 leads to B cell apoptosis. As part of the immune system B cells produce antibodies; hence B cell depletion affects humoral immunity. However this depletion allows for the reduction of abnormal B cells in conditions like cancer and autoimmune diseases where aberrant B cell activity plays a harmful role.
Pathways
CD20 does not belong to a multi-component signaling complex but plays a role in calcium signaling in B cells. It modulates calcium influx which is critical for B cell activation and regulation. The pathways involving CD20 are associated with B-cell receptor signaling an essential mechanism regulating B cell survival and proliferation. Other proteins like SYK and BLNK are involved in the extended signaling cascade triggered by B-cell receptor activation.
Rituximab plays an important role in the treatment of B-cell non-Hodgkin lymphomas and rheumatoid arthritis. It targets and removes malignant B cells in lymphoma offering an effective therapy alongside traditional chemotherapies. In rheumatoid arthritis rituximab reduces B cell-mediated inflammation and tissue damage. Rituximab's specificity for CD20 allows it to reduce disease-associated B cells without destroying all B cells minimizing unintended consequences on the immune system.